CSP-9222 is the lead compound from a family of caspase activators that have been in-licensed from Bayer Healthcare LLC. These novel, small molecules have been identified as activators of programmed cell death.
Unlike normal cells, many tumor cell types have lost the ability to undergo the normal process of programmed cell death, known as apoptosis. By activating the caspase pathway, tumor cells can be triggered to undergo apoptosis resulting in cell death.
Preclinical data with CSP-9222 in numerous preclinical animal models, including taxane-resistant tumor cells, indicate anti-tumor activity across a broad spectrum of tumor cell types. Both intravenous and oral administration of CSP-9222 has resulted in anti-tumor activity in various animal models. Thus, CSP-9222 offers the potential for a novel therapy in the treatment of a variety of cancers.